

09 Nov 2021 | **News**

QUOTED. Ryan Zimmerman.

by

Alcon is making a return to the minimally invasive glaucoma surgery market by acquiring Ivantis for at least \$475m, the companies said. See what BTIG analyst Ryan Zimmerman said about it here.

"Alcon has long been rumored to have an option to acquire Ivantis but there were hurdles including reimbursement, lawsuits, and other factors that delayed Alcon's interest." – Ryan Zimmerman, analyst, BTIG

- Find out more: [Alcon Sees Big Opportunity In Glaucoma Surgery; Buys Ivantis For \\$475M](#)

[Click here](#) for a free trial of *Medtech Insight*